Researchers from West China Hospital, Sichuan University, have revealed a significant association between COVID-19 and acute kidney disorders (AKD), including acute kidney injury (AKI), that varies over time…. read more.
Travere Therapeutics, Inc., announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27,… read more.
Whether dialysis is the best option for kidney failure and, if so, when to start, may deserve more careful consideration, according to a new study. For older adults… read more.
A new study from UC Davis Health could help to increase the supply of donor kidneys. Researchers have found that transplant patients who receive kidneys infected with the parasite toxoplasma… read more.
Aurinia Pharmaceuticals Inc. announced an oral presentation at the European Alliance of Associations for Rheumatology (EULA R) 2024 taking place in Vienna, Austria June 12-15. The data reinforces… read more.
MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) </p. Jardiance has been available in Japan… read more.
New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is… read more.
The Ministry of Health, Labor and Welfare (MHLW) on November 21 ordered label revisions for five anticoagulants to newly advise the risk of acute kidney injury, including Bristol… read more.
Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant… read more.
Hansa Biopharma announced randomization for the US ConfIdeS trial is expected to conclude in mid-2024. The ConfIdeS trial is an open-label, controlled, randomized Phase III trial evaluating 12-month… read more.
Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular… read more.
Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine recently conducted a large-scale analysis to assess the impact of a newly introduced equation used to evaluate… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
